Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Link

Showing results (221-230 of 328) with videos related to

Pageof 33
Sort By:
Hematological Oncology|June 11, 2016
FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohortsHervé Ghesquières, Beth R Larrabee, Corinne Haioun, et al.
British Journal of Haematology|March 10, 2026
Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypesGeorge A Cholack, Raphael Mwangi, Prokop Vodička, et al.
American Journal of Hematology|April 12, 2014
Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cellsClive S Zent, Ronald P Taylor, Margaret A Lindorfer, et al.
American Journal of Hematology|March 18, 2014
Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphomaHeather L Gustafson, Song Yao, Bryan H Goldman, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2013
CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosisBridget Charbonneau, Alice H Wang, Matthew J Maurer, et al.
British Journal of Haematology|May 30, 2018
Human Pegivirus infection and lymphoma risk and prognosis: a North American studyAngelo Fama, Jinhua Xiang, Brian K Link, et al.
American Journal of Hematology|September 18, 2014
Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphomaThomas E Witzig, Matthew J Maurer, Thomas M Habermann, et al.
Blood|March 6, 2012
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter studyMyron S Czuczman, Luis Fayad, Vincent Delwail, et al.
Leukemia|October 14, 2017
Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphomaG Hu, S Dasari, Y W Asmann, et al.
Clinical Epidemiology|December 10, 2019
Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing ChemotherapyMichael R Clausen, Matthew J Maurer, Sinna Pilgaard Ulrichsen, et al.
Pageof 33

Showing results (221-230 of 328) with videos related to

Sort By:
Pageof 33
Hematological Oncology|June 11, 2016
FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohortsHervé Ghesquières, Beth R Larrabee, Corinne Haioun, et al.
British Journal of Haematology|March 10, 2026
Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypesGeorge A Cholack, Raphael Mwangi, Prokop Vodička, et al.
American Journal of Hematology|April 12, 2014
Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cellsClive S Zent, Ronald P Taylor, Margaret A Lindorfer, et al.
American Journal of Hematology|March 18, 2014
Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphomaHeather L Gustafson, Song Yao, Bryan H Goldman, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2013
CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosisBridget Charbonneau, Alice H Wang, Matthew J Maurer, et al.
British Journal of Haematology|May 30, 2018
Human Pegivirus infection and lymphoma risk and prognosis: a North American studyAngelo Fama, Jinhua Xiang, Brian K Link, et al.
American Journal of Hematology|September 18, 2014
Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphomaThomas E Witzig, Matthew J Maurer, Thomas M Habermann, et al.
Blood|March 6, 2012
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter studyMyron S Czuczman, Luis Fayad, Vincent Delwail, et al.
Leukemia|October 14, 2017
Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphomaG Hu, S Dasari, Y W Asmann, et al.
Clinical Epidemiology|December 10, 2019
Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing ChemotherapyMichael R Clausen, Matthew J Maurer, Sinna Pilgaard Ulrichsen, et al.
Pageof 33